Federated Hermes
LGND icon

Federated Hermes’s Ligand Pharmaceuticals LGND Stock Holding History

Federated Hermes’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-31,714
Closed -$2.32M – 2090
2024
Q1 		$2.32M Sell
31,714
-7,250
-19% -$535K 0.01% 893
2023
Q4 		$2.78M Sell
38,964
-10,060
-21% -$594K 0.01% 864
2023
Q3 		$2.94M Sell
49,024
-245
-0.5% -$16.1K 0.01% 823
2023
Q2 		$3.55M Sell
49,269
-1,959
-4% -$147K 0.01% 789
2023
Q1 		$3.77M Buy
51,228
+23,661
+86% +$1.68M 0.01% 775
2022
Q4 		$1.84M Buy
27,567
+27,549
+153,050% +$1.79M 0.01% 937
2022
Q3 		$1K Hold
18
– – ﹤0.01% 2054
2022
Q2 		$1K Sell
18
-10,958
-100% -$622K ﹤0.01% 2052
2022
Q1 		$770K Sell
10,976
-3,760
-26% -$273K ﹤0.01% 1334
2021
Q4 		$1.42M Sell
14,736
-5
-0% -$462 ﹤0.01% 1152
2021
Q3 		$1.28M Sell
14,741
-90,058
-86% -$6.97M ﹤0.01% 1191
2021
Q2 		$8.58M Buy
104,799
+83,960
+403% +$6.98M 0.02% 709
2021
Q1 		$1.98M Sell
20,839
-37,146
-64% -$3.51M ﹤0.01% 1109
2020
Q4 		$3.6M Buy
57,985
+20,500
+55% +$1.17M 0.01% 899
2020
Q3 		$2.23M Buy
37,485
+34,010
+979% +$2.32M 0.01% 950
2020
Q2 		$242K Sell
3,475
-15
-0.4% -$951 ﹤0.01% 1607
2020
Q1 		$158K Sell
3,490
-753
-18% -$42.7K ﹤0.01% 1601
2019
Q4 		$276K Sell
4,243
-1,036
-20% -$69.2K ﹤0.01% 1550
2019
Q3 		$328K Sell
5,279
-945
-15% -$59.3K ﹤0.01% 1507
2019
Q2 		$443K Sell
6,224
-5,659
-48% -$417K ﹤0.01% 1453
2019
Q1 		$932K Buy
11,883
+346
+3% +$26.2K ﹤0.01% 1333
2018
Q4 		$977K Sell
11,537
-34,025
-75% -$3.63M ﹤0.01% 1294
2018
Q3 		$7.8M Sell
45,562
-59,657
-57% -$8.99M 0.02% 665
2018
Q2 		$13.6M Buy
105,219
+78,471
+293% +$8.76M 0.04% 351
2018
Q1 		$2.76M Sell
26,748
-9,459
-26% -$935K 0.01% 836
2017
Q4 		$3.09M Buy
36,207
+13,321
+58% +$1.15M 0.01% 773
2017
Q3 		$1.94M Buy
+22,886
New +$1.81M 0.01% 929
2016
Q3 		– Sell
-7,428
Closed -$553K – 2143
2016
Q2 		$553K Buy
7,428
+7,378
+14,756% +$548K ﹤0.01% 1253
2016
Q1 		$3K Buy
+50
New +$3.04K ﹤0.01% 1939
2015
Q4 		– Sell
-2,332
Closed -$125K – 2123
2015
Q3 		$125K Buy
2,332
+1,139
+95% +$69.1K ﹤0.01% 1553
2015
Q2 		$75K Buy
+1,193
New +$65.1K ﹤0.01% 1612
2015
Q1 		– Sell
-90
Closed -$3K – 2043
2014
Q4 		$3K Sell
90
-40,913
-100% -$1.33M ﹤0.01% 1892
2014
Q3 		$1.2M Buy
41,003
+7,228
+21% +$240K ﹤0.01% 1148
2014
Q2 		$1.31M Buy
33,775
+15,639
+86% +$635K ﹤0.01% 1104
2014
Q1 		$761K Buy
18,136
+16,091
+787% +$671K ﹤0.01% 1237
2013
Q4 		$67K Sell
2,045
-1,360
-40% -$44.3K ﹤0.01% 1630
2013
Q3 		$92K Sell
3,405
-2,279
-40% -$64.1K ﹤0.01% 1574
2013
Q2 		$133K Buy
+5,684
New +$102K ﹤0.01% 1488

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Federated Hermes's LGND Position: Q2 2024 in Review

Federated Hermes sold out of Ligand Pharmaceuticals (LGND) in Q2 2024, closing a stake of 31,714 shares — an estimated $2.32M sold.

Federated Hermes first reported a position in LGND in Q2 2013 and held it in 38 quarters. The position peaked at $13.6M in Q2 2018. 234 funds tracked by Wall St. Rank hold LGND as of Q2 2024.

  • Federated Hermes reported no remaining Ligand Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Federated Hermes sold 31,714 Ligand Pharmaceuticals shares in Q2 2024, an estimated $2.32M.
  • Federated Hermes first reported a position in Ligand Pharmaceuticals in Q2 2013 and held it in 38 quarters.
  • Federated Hermes's Ligand Pharmaceuticals position peaked at $13.6M in Q2 2018.
  • 234 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2024.

Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.